Jane Street’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $19.2M | Sell |
349,400
-645,900
| -65% | -$26.4M | ﹤0.01% | 2185 |
|
|
2026
Q1 | $33.1M | Buy |
995,300
+306,000
| +44% | +$9.12M | ﹤0.01% | 1349 |
|
|
2025
Q4 | $20.5M | Buy |
689,300
+290,800
| +73% | +$9.5M | ﹤0.01% | 1604 |
|
|
2025
Q3 | $14.4M | Buy |
398,500
+152,800
| +62% | +$5.03M | ﹤0.01% | 1982 |
|
|
2025
Q2 | $8.84M | Sell |
245,700
-64,400
| -21% | -$2.4M | ﹤0.01% | 2288 |
|
|
2025
Q1 | $12.2M | Sell |
310,100
-218,100
| -41% | -$7.34M | ﹤0.01% | 1756 |
|
|
2024
Q4 | $15.9M | Buy |
528,200
+334,900
| +173% | +$9.61M | ﹤0.01% | 1461 |
|
|
2024
Q3 | $4.52M | Buy |
193,300
+83,100
| +75% | +$1.81M | ﹤0.01% | 3029 |
|
|
2024
Q2 | $1.96M | Sell |
110,200
-34,900
| -24% | -$557K | ﹤0.01% | 4508 |
|
|
2024
Q1 | $2.21M | Sell |
145,100
-150,900
| -51% | -$2.4M | ﹤0.01% | 3952 |
|
|
2023
Q4 | $5.06M | Buy |
296,000
+95,500
| +48% | +$1.11M | ﹤0.01% | 2835 |
|
|
2023
Q3 | $1.68M | Sell |
200,500
-100,800
| -33% | -$1.41M | ﹤0.01% | 4336 |
|
|
2023
Q2 | $7.48M | Buy |
301,300
+202,900
| +206% | +$5.24M | ﹤0.01% | 2233 |
|
|
2023
Q1 | $1.48M | Sell |
98,400
-126,100
| -56% | -$1.92M | ﹤0.01% | 4331 |
|
|
2022
Q4 | $2.66M | Buy |
224,500
+105,200
| +88% | +$764K | ﹤0.01% | 3400 |
|
|
2022
Q3 | $706K | Sell |
119,300
-8,600
| -7% | -$56.4K | ﹤0.01% | 6054 |
|
|
2022
Q2 | $544K | Sell |
127,900
-51,100
| -29% | -$319K | ﹤0.01% | 6588 |
|
|
2022
Q1 | $1.7M | Sell |
179,000
-42,500
| -19% | -$492K | ﹤0.01% | 5064 |
|
|
2021
Q4 | $4.21M | Sell |
221,500
-18,100
| -8% | -$470K | ﹤0.01% | 3120 |
|
|
2021
Q3 | $7.97M | Buy |
239,600
+56,700
| +31% | +$1.75M | ﹤0.01% | 2100 |
|
|
2021
Q2 | $7.09M | Buy |
182,900
+72,900
| +66% | +$2.86M | ﹤0.01% | 2140 |
|
|
2021
Q1 | $5.3M | Buy |
110,000
+43,100
| +64% | +$2.07M | ﹤0.01% | 2325 |
|
|
2020
Q4 | $3.48M | Sell |
66,900
-13,700
| -17% | -$463K | ﹤0.01% | 2604 |
|
|
2020
Q3 | $2.16M | Buy |
80,600
+38,000
| +89% | +$874K | ﹤0.01% | 2917 |
|
|
2020
Q2 | $830K | Buy |
42,600
+31,000
| +267% | +$499K | ﹤0.01% | 4337 |
|
|
2020
Q1 | $114K | Buy |
+11,600
| New | +$147K | ﹤0.01% | 4898 |
|
|
2018
Q4 | – | Sell |
-33,900
| Closed | -$190K | – | 5705 |
|
|
2018
Q3 | $190K | Buy |
33,900
+12,300
| +57% | +$141K | ﹤0.01% | 4707 |
|
|
2018
Q2 | $284K | Buy |
+21,600
| New | +$297K | ﹤0.01% | 4184 |
|
Other funds holding TGTX
SCM
CAM
Jane Street's TGTX Position: Q2 2026 in Review
Jane Street reduced its TG Therapeutics (TGTX) stake by 14% in Q2 2026, selling an estimated $11.8M and leaving 1,752,646 shares worth $96.3M. The position accounts for 0.01% of the portfolio, ranked #952.
Jane Street first reported a position in TGTX in Q2 2013 and has held it in 33 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.
- Jane Street held 1,752,646 shares of TG Therapeutics worth $96.3M as of Q2 2026.
- Jane Street sold 289,023 TG Therapeutics shares in Q2 2026, an estimated $11.8M.
- TG Therapeutics made up 0.01% of Jane Street's portfolio in Q2 2026, its #952 holding.
- Jane Street first reported a position in TG Therapeutics in Q2 2013 and has held it in 33 quarters since.
- 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.
Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.